Immunetrics’ disease models span across acute inflammation, chronic autoimmune conditions, and immuno-oncology.
Immunetrics has developed a suite of models which have been trained to publically available data and are constantly evolving to support new research outcomes. These models can be used in their current state, extended and trained to richer, proprietary data sets, or otherwise customized to meet specific needs.
Autoimmune Disease Models
Immunetrics’ models include both explicitly represented biological species (e.g. specific cell types and proteins) as well as abstract variables that represent aggregate behavior of a set of biological species (e.g. higher-level disease physiology). These species form a network of known mechanisms that are modulated by therapies and link to clinical endpoints for prediction of clinical trial results.
Rheumatoid Arthritis (RA)
Model supports inadequate response to standard of care (methotrexate) and TNF inhibitors.
Key Model Outputs | Supported Therapies |
Swollen/Tender Joint Count (SJC28/TJC28) ACR20/50/70 DAS28(3)-CRP/ESR Low Disease Activity / Remission Cell Counts Cytokines and Biomarkers (including CRP & ESR) | Methotrexate Corticosteroids JAK Inhibitors (Baricitinib, Tofacitinib, Upadacitinib) Anti-TNF (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab) Anti-IL6 (Tocilizumab) Anti-T and B cell therapies (Abatacept, Rituximab) BTK inhibitors (Fenebrutinib, Elsubrutinib) |
PSORIATIC ARTHRITIS (PsA)
Key Model Outputs | Supported Therapies |
Swollen/Tender Joint Count (SJC28/TJC28) ACR20/50/70 DAS28(3)-CRP/ESR PASI50/75/90/100 Cell Counts Cytokines and Biomarkers | Methotrexate Corticosteroids T cell inhibitor (Abatacept) TNF inhibitors (Adalimumab, Etanercept, Golimumab, Certolizumab Pegol) anti-IL17 (Ixekizumab, Secukinumab) anti-IL12/23 (Ustekinumab) anti-IL23 (Guselkumab and Risankizumab) Jak inhibitors (Tofacitinib and Upadacitinib) Tyk2 inhibitors (Deucravacitinib) |
Psoriasis (PsO)
Key Model Outputs | Supported Therapies |
---|---|
BSA PASI50/75/90/100 Cell Counts Cytokines and Biomarkers | anti-IL17 (Ixekizumab and Secukinumab) anti-IL12/23 (Ustekinumab) anti-IL23 (Guselkumab and Risankizumab) Jak inhibitor (Tofacitinib) Tyk2 inhibitor (Deucravacitinib) |
Atopic Dermatitis (AD)
Key Model Outputs | Supported Therapies |
---|---|
EASI SCORAD EASI75 IGA Responder Cell Counts Cytokines and Biomarkers | Corticosteroids Calcineurin Inhibitors JAK Inhibitors (abrocitinib, baricitinib, upadacitinib) anti-IL13 (tralokinumab) anti-IL4r (dupilumab) |
Ulcerative Colitis (UC)
Model supports local and central endoscopic assessments, Full and Partial Mayo Score, and Induction and Maintenance trial phases.
Key Model Outputs | Supported Therapies |
---|---|
Full / Partial Mayo score Response / Remission Mucosal healing Cytokines and Biomarkers | Corticosteroids 5ASA TNF inhibitors (Adalimumab, Golimumab, Infliximab) JAK inhibitors (Filgotinib, Tofacitinib, Upadacitinib) S1P receptor antagonists (Ozanimod) anti-chemotaxis drugs (Vedolizumab, Ontamalimab, Etrolizumab) anti-IL12/23 (Ustekinumab) anti-IL23 (Guselkumab, Mirikizumab) |
Systemic Lupus Erythematosus (SLE)
Model requires client supplied individual patient data to train clinical measure outputs.
Key Model Outputs | Supported Therapies |
---|---|
CLASI CLASI Responder Swollen Joint Count (SJC) Steroid Taper Cytokines and Biomarkers Individual patient data is required to support: SRI4 BICLA SLEDAI Low Disease Activity | Corticosteroids (including tapering protocols) anti-BDCA2 (Litifilimab) anti-IFNa (Sifalimumab, Anifrolumab) anti-BAFF (Belimumab, Tabalumab) anti-IL12/23 (Ustekinumab) JAK inhibitor (Baricitinib) |
Crohn’s Disease (CD)
Model requires client supplied individual patient data to train clinical measure outputs.
Key Model Outputs | Supported Therapies |
---|---|
CDEIS SES-CD CDAI CDAI-70/100 Remission Response Mucosal Healing Stool Frequency Cytokines and Biomarkers Cell counts | JAK Inhibitors (upadacitinib, filgotinib, tofacitinib) anti-TNF (adalimumab, infliximab, certolizumab) anti-IL12/23 (ustekinumab) anti-IL17 (brodalumab, secukinumab) anti-IL23 (risankizumab) anti cell trafficking therapies (vedolizumab, anti-MadCAM) anti T cell therapies (abatacept) |
Immuno-Oncology Models
Acute Myeloid Leukemia (AML)
For this model, response measures are based on blast counts.
Key Model Outputs | Supported Therapies |
---|---|
Best Overall Response (BOR): · Complete Response (CR) · Partial Response (PR) · Stable Disease (SD) · Partial Disease (PD) Response vs Non-response Minimal Residual Disease (MRD = < 0.1% Blasts) Death Duration of Response (DoR) Relapse Disease-specific Biomarkers: · Percent Blasts (Bone marrow and blood) | Hypomethylating Agents (azacitidine) Chemotherapies (cytarabine) BCL-2 inhibitor (venetoclax) Monoclonal antibodies (e.g. anti-CD47) |
Multiple Myeloma (MM)
For this model, the response measures are based on the percent change in M protein, FLCs, and MM clones. The Antibody Drug Conjugates and NK Cell Engager implementations requires client supplied data
Key Model Outputs | Supported Therapies |
---|---|
Best Overall Response (BOR): · Complete Response (CR) · Partial Response (PR) · Stable Disease (SD) · Partial Disease (PD) Overall Response Rate (ORR) Time to Response (TTR) Duration of Response (DoR) Disease Specific Biomarkers: · Soluble B-Cell Maturation Antigen (sBCMA) · M-Protein · Soluble Free Light Chain (sFLC) | Immunomodulatory Drugs (IMiDs) Antibody-Drug Conjugates (ADCs) Immune Cell Engagers (NK and T cell) Monoclonal Antibodies (Daratumumab, Elotuzumab) Chimeric Antigen Receptor T-cell Therapies (CAR T) Steroids (Dexamethasone) |
Non-Small Cell Lung Cancer (NSCLC)
Key Model Outputs | Supported Therapies |
---|---|
Percent change in Tumor Diameter Best Overall Response (BOR) Progressive Disease (PD) Stable Disease (SD) Responders (RR) | Monoclonal Antibodies: · anti-PD-1 (Nivolumab and Pembrolizumab) · anti-CTLA-4 (Ipilimumab) · anti-PDL1 (Atezolizumab) · TLR9 agonist (PF-3512676) · Interferon alfa-2a (Roferon A) · Epacadostat Chemotherapies: · alkylating agents (Carboplatin) · cytoskeletal drugs (Paclitaxel) · Gemcitabine · Pemetrexed |
Diffuse Large B-Cell lymphoma (dlbcl)
Key Model Outputs | Supported Therapies |
---|---|
Complete Responder (CR) Partial Responder (PR) Tumor Cell Number | Chimeric Antigen Receptor T cell Therapies (CAR-T): · ricAxiabtagene ciloleucel (axi-cel) · tisgenlecleucel (CTL019) R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) Immunomodulatory Drugs (IMiDs) (Lenalidomide) |